PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33867777-0	2021	The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2.	Levalbuterol	40-54	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	60-65	
33867777-1	2021	In this study, we have investigated the binding mechanism of two FDA-approved drugs (ivermectin and levosalbutamol) with the spike protein of SARs-CoV-2 using three different computational modeling techniques.	Levalbuterol	100-114	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	125-130	
33867777-3	2021	Ivermectin binds with LEU492, GLN493, GLY496, and TRY505 residues in the spike protein through hydrogen bonds and levosalbutamol binds with TYR453 and TYR505 residues.	Levalbuterol	114-128	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	73-78	
33867777-4	2021	Using density functional theory (DFT) studies, we have calculated the binding energies between ivermectin and levosalbutamol with residues in spike protein which favor their binding are - 22.4 kcal/mol and - 21.08 kcal/mol, respectively.	Levalbuterol	110-124	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	142-147	
33867777-7	2021	Three different computer modeling techniques reveal that ivermectin is more stable than levosalbutamol in the active site of spike protein where hACE2 binds.	Levalbuterol	88-102	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	125-130